To further examine the therapeutic effect of SRA silencing in DCs, we treated B16-gp100 melanoma bearing mice with the hsp110-gp100 vaccine-loaded DCs that have received either SRA shRNA or scramble shRNA. The gene discussed is HSPH1; the disease is melanoma.